Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04794387 · ClinicalTrials.gov registry record
The Lymphoma and Leukemia Society Amended COVID-19 Registry
A clinical trial, sponsored by Blood Cancer United.
- Completed
- Registry status
- 1,000
- Enrollment target
NCT04794387: Completed study, sponsored by Blood Cancer United.
NCT04794387 is a clinical trial that has completed, run by Blood Cancer United. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04794387 has completed, sponsored by Blood Cancer United.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
The LLS COVID-19 Registry is being amended to invite people who participated in the LLS COVID-19 Registry and did not develop antibodies after receiving a complete COVID-19 vaccination, as well as people with blood cancer who did not participate in the initial LLS COVID-19 Registry and also did not develop antibodies after receiving a complete COVID-19 vaccination, to participate in this amended LLS COVID-19 Registry.
Primary Outcome
Observational Study
Interventions
- BIOLOGICAL Amended LLS COVID-19 Registry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2022-12-13 |
What the finished NCT04794387 record still lists
NCT04794387 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Amended LLS COVID-19 Registry is the first listed.
NCT04794387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04794387 about?
NCT04794387 is a clinical study titled "The Lymphoma and Leukemia Society Amended COVID-19 Registry". The LLS COVID-19 Registry is being amended to invite people who participated in the LLS COVID-19 Registry and did not develop antibodies after receiving a complete COVID-19 vaccination, as well as people with blood cancer who did not participate in the initial LLS COVID-19 Registry and also did not ...
What is the current status of trial NCT04794387?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2021-08-27. Estimated completion is 2022-12-13.
What interventions are being tested in trial NCT04794387?
The interventions under investigation include: Amended LLS COVID-19 Registry (BIOLOGICAL).
Who is sponsoring clinical trial NCT04794387?
This trial is sponsored by Blood Cancer United, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI